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We conducted a phase II study of docetaxel in combination with 
everolimus, a mammalian target of rapamycin (mTOR) inhibitor, for 
salvage therapy of advanced non–small-cell lung cancer (NSCLC) 
based on promising preclinical and early-phase clinical data. Patients 
with advanced-stage NSCLC treated with one or two previous sys-
temic therapy regimens were given docetaxel (60 mg/m2) and evero-
limus (5 mg orally once daily on days 1–19) every 3 weeks. Archived 
tumor specimens were evaluated for markers of mTOR pathway acti-
vation (total and phosphorylated mTOR, Akt, S6, eIF4e, and 4EBP1). 
Twenty-eight patients were enrolled (median age: 62 years; male: 
13; Caucasians: 19; adenocarcinoma: 20; performance status 0, 3; 
performance status 1, 23; 1 previous regimen, 16). A median of 3.5 
cycles of therapy was administered. Two patients experienced partial 
response and 15 had stable disease (clinical benefit rate, 70%). The 
6-month progression-free survival rate was 5%, and the median over-
all survival was 9.6 months. Low pAkt expression correlated with 
clinical benefit rate (p = 0.01) but not with progression-free survival 
or overall survival. The combination of everolimus and docetaxel was 
tolerated well, but the efficacy was relatively modest in an unselected 
population of patients with NSCLC.
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The mammalian target of rapamycin (mTOR) regulates cell survival, growth, and metabolism.1 It is aberrantly 
activated in a variety of cancers including non–small-cell lung 
cancer (NSCLC). Activation of mTOR pathway is also known 
to contribute to resistance associated with taxane therapy.2 
Everolimus is an analogue of sirolimus that inhibits the 
mTOR pathway. The U.S. Food and Drug Administration has 
approved everolimus for the treatment of advanced renal cell 
carcinoma. When used as monotherapy in advanced NSCLC, 
the response rate with everolimus is low at less than 10%.3 
In preclinical studies, everolimus exerts synergistic anticancer 
effects with docetaxel in a variety of cell lines.4,5 We previously 
reported that docetaxel and everolimus could be combined 
safely in patients with advanced NSCLC at the doses of 
60 mg/m2 and 5 mg orally once daily, respectively.6 The dose-
limiting toxicities were grade 3 fatigue, grade 3 mucositis, 
and grade 3/4 neutropenia with fever. Our phase I experience 
also documented a disease stabilization rate of approximately 
55% in patients with advanced NSCLC that had progressed 
with multiple previous chemotherapy regimens. Therefore, 
we conducted a phase II study to evaluate the efficacy of the 
combination of docetaxel and everolimus as salvage therapy 
in patients with advanced NSCLC.
PATIENTS AND METHODS
Patient Eligibility
Patients with stage IIIB/IV NSCLC that had progressed 
after one or two previous chemotherapy regimens for advanced 
NSCLC were eligible. Other salient inclusion criteria were 
Eastern Cooperative Oncology Group performance status of 
0, 1, or 2; life expectancy more than 12 weeks; age more than 
18 years; adequate bone marrow, hepatic, and renal function; 
and willingness to sign informed consent. Women of repro-
ductive age group were required to have a negative serum 
pregnancy test. Patients with uncontrolled brain metastasis, 
active bleeding diathesis, use of therapeutic doses of warfa-
rin for anticoagulation, known hypersensitivity to docetaxel, 
inability to swallow everolimus pills, and/or chronic treatment 
with systemic corticosteroids or other immunosuppressive 
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agents were excluded. Patients with gastrointestinal dysfunc-
tion that could interfere with everolimus absorption, previous 
therapy with docetaxel, and known seropositivity for human 
immunodeficiency virus were also excluded. The institutional 
review board at both the participating institutions approved 
the study protocol.
Treatment Plan
Docetaxel was administered as a 60-minute intravenous 
infusion of 60 mg/m2 on day 1 of each cycle. Everolimus was 
prescribed at a dose of 5 mg/day on days 1 to 19 of each cycle. 
Treatment cycles were repeated every 3 weeks. Prophylactic 
colony-stimulating factors were not allowed for the first cycle 
of therapy. Treatment cycles were continued for a maximum of 
six cycles of therapy, after which patients with stable  disease 
or an objective response were allowed to continue everolimus 
alone as monotherapy at the same schedule as in the combi-
nation regimen. Treatment was continued until disease pro-
gression, unacceptable toxicity, or withdrawal of informed 
consent.
Toxicity was graded by the National Cancer Institute 
Common Terminology Criteria verison 3.0. Dose of the agent 
most likely to have caused the toxicity was reduced for severe 
toxicity. Docetaxel was reduced by 10-mg/m2 decrements, 
and everolimus by 2.5-mg/day decrements. A maximum of 
two dose reductions were allowed per patient, after which he 
or she had to come off study if further modifications were 
required. Dose re-escalation was not allowed. Before the ini-
tiation of a new cycle of therapy, the patient was required to 
have an absolute neutrophil count of more than 1500 per cubic 
microliter and a platelet count of more than 100,000 per cubic 
microliter. In addition, all treatment-related toxicity had to 
resolve to grade 1 or less. If these conditions were not met, 
treatment cycles were delayed up to a maximum of 2 weeks to 
allow for recovery.
Study Assessments
At baseline, patients were required to undergo a history 
and physical examination, assessment of performance status, 
serum pregnancy test (if clinically indicated), complete blood 
count with differential count, and serum chemistry. Positron 
emission technique (PET) scan was performed at baseline 
and after cycle 2. All subsequent assessments were performed 
with a computed tomography scan every two cycles of ther-
apy. Responses were assessed by the Response Evaluation 
Criteria in Solid Tumors version 1.0.7 For subsequent cycles, 
history and physical examination, toxicity assessment, com-
plete blood count with differential count, serum chemistry, 
and lipid profile were evaluated on day 1.
Statistical Methods
The primary objectives of the study were to determine 
the objective response rate and the 6-month progression-free 
survival (PFS) rate with the combination of docetaxel and 
everolimus. The secondary objectives were to evaluate the 
safety profile and the overall survival. With an estimated sam-
ple size of 48 patients, the study would have a 95% power at 
the 19.7% level of significance to detect an improvement in the 
6-month PFS rate from 25% (historical control) to 42% with 
the novel combination regimen. Twenty-seven patients were 
enrolled to the first stage of the study. If five or fewer objec-
tive responses were observed, the study was to be terminated 
for lack of efficacy, and more than 12 responses would prompt 
the termination of the study with acceptance of the alternate 
hypothesis. PET scans were performed at baseline and after 
two cycles to determine metabolic response to mTOR inhibi-
tion as an exploratory end point.
Biomarker Evaluation
Archival diagnostic tumor samples were evaluated for 
upstream and downstream markers of mTOR pathway acti-
vation (total and phosphorylated mTOR, Akt, S6, eIF4e, and 
4EBP1) by immunohistochemistry. The staining intensity of 
biomarker expression was used for this analysis with the ranges 
expressed as 0, 1+, 2+, or 3+. General linear models were used 
to test the differences in biomarker expression across different 
categories of tumor response and histology. The relationship 
between the biomarker expression and the patient’s age was 
assessed by Spearman correlation coefficient and Wald’s test.
RESULTS
Twenty-eight patients were accrued between April 2009 
and July 2010. Women and African Americans accounted for 
54% and 28% of the study population, respectively. Sixteen 
patients (58%) had received only one previous chemotherapy 
regimen (Table 1). The median number of cycles of docetaxel 
TABLE 1.  Patient Demographics
Number of patients 28
Median age 62 years (40–81)
Sex
 Male 13
 Female 15
Race
 Caucasian 19
 African American  8
 Other  1
Histology
 Adenocarcinoma 20
 Squamous cell  5
 NOS  3
Performance status
 0  3
 1 23
 2  2
Stage
  IIIB  2
 IV 26
Number of prior regimens
 1 16
 2 12
NOS, not otherwise specified.
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and everolimus combination was 3.5 (range, 1–6). Ten patients 
received everolimus as maintenance therapy for a median of 
an additional two cycles (range, 1–7).
Efficacy
Twenty-four patients completed the first two cycles 
of therapy and were evaluable per protocol for response 
determination. Partial responses were observed in two and 
stable disease in 15, resulting in an overall clinical benefit 
rate of 71% (Table 2). Of the 28 patients, 20 had documented 
disease progression during the course of the study, and the 
median time to disease progression was 4.42 months. The 
median overall survival was 9.6 months. Paired PET scans 
were performed in 19 patients. The median standardized 
uptake value of the dominant tumor mass was 8.3 at baseline 
(range, 2.8–19) and 7.2 after therapy (range, 3.2–21). There 
was no correlation between fluorodeoxy glucose uptake and 
the Response Evaluation Criteria in Solid Tumors responses.
Toxicity
Neutropenia, anorexia, fatigue, and hyperlipidemia 
were the most frequently reported toxicities (Table 3). Serious 
adverse events included fever with neutropenia (n = 3), 
 pneumonia (n = 1), death (n = 1), and small bowel obstruction 
(n = 1). Six patients were removed from the study because 
of toxicities. The death resulted from pulmonary embolism as 
the precipitating event. Among the toxicities, hyperlipidemia, 
hyperglycemia, and mucositis were likely related to evero-
limus, whereas the remaining toxicities was attributable to 
docetaxel alone or the combination regimen.
Biomarker Analysis
Tumor samples were available for biomarker analysis in 
13 of 28 patients. High pAkt expression was observed in patients 
with progressive disease (p = 0.01) and in patients with squa-
mous or not otherwise specified histology (p = 0.04). The levels 
of expression of S6 (p = 0.08), pS6 (p = 0.09), and p-mTOR (p 
= 0.07) were different among disease-response categories. There 
was no significant correlation between the tested biomarkers and 
patient survival outcomes (PFS or overall survival).
DISCUSSION
The promising preclinical and early-phase clinical 
observations were not confirmed in this phase II study with 
the combination of docetaxel and everolimus. An important 
limitation of our study is that the dose of docetaxel at 
60 mg/m2 is lower than that approved by the U.S. Food and 
Drug Administration (75 mg/m2). In our preceding phase 
TABLE 2.  Efficacy
Best response (N = 24) n
Complete response 0 (0)
Partial response 2 (8%)
Stable disease 15 (63%)
Progressive disease 7 (29%)
Median time to progression 4.42 mo
Six-month PFS rate 5%
Median survival 9.6 mo
PFS, progression-free survival.
TABLE 3.  Toxicitya (represented by worst grade, occurring 
in at least one patient)
Adverse event (N = 28) Grade 2 Grade 3 Grade 4
Cough 4 — —
Leukopenia 2 — —
Elevated glucose 6 2 —
Low albumin 2 1 —
Back pain 2 — —
Constipation 2 — —
Fatigue 9 1 —
Anemia 4 3 —
High cholesterol 2 — —
Leg pain 2 — —
Alopecia 1 — —
Anorexia 3 — —
Hypertension 1 — —
Rash 2 — —
Mucositis 1 1 —
Elevated triglycerides 2 — —
Lowered phosphorous 2 — —
Lowered calcium 1 — —
Pneumothorax 1 — —
Nail changes 1 — —
Lowered potassium 1 — —
Hyperglycemia 1 2 —
Elevated creatinine 1 — —
Thrombocytopenia 1 — —
Weight loss 1 — —
Pain 3 — —
Peripheral neuropathy 2 — —
Hypoxia 1 — —
Infection 2 — —
Edema 1 — —
Stomatitis 1 — —
Dyspnea 1 2 —
Diarrhea 1 — —
Hyponatremia — 1 —
Elevated alkaline phosphatase — 1 —
Small bowel resection — 1 —
Neutropenia — 4 —
Dyspepsia — 1 —
Dizziness — 1 —
Leucopenia — 1 —
Hypophosphatemia — 1 —
Headache — 1 —
Pneumonia — 1 —
Thrombosis — 1 —
aTreatment discontinuation resulted from severe neutropenia (n = 3), pneumonia 
(n = 1), decline in performance status (n = 1), and small bowel obstruction (n = 1).
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I study, we were unable to combine the standard dose of 
docetaxel with a clinically relevant dose of everolimus. The 
observed median survival of nearly 10 months could have 
been influenced by poststudy therapy regarding which data 
were not collected. In studies on lung cancer, everolimus 
was given at a dose of 5 mg/day, whereas in diseases where 
it has demonstrated robust efficacy such as breast cancer 
and renal cancer, it is given at a dose of 10 mg/day.8,9 This 
raises the question as to whether at the dose of 5 mg/day, 
everolimus can exert its effects on upstream and downstream 
targets in the lung cancer tissue. To assess the differences in 
the pharmacodynamic effects between the 5mg/day and the 
10 mg/day dose, our group is conducting a phase Ib “window 
of opportunity” study in patients with resectable NSCLC 
(NCT00401778). The biomarker discovery efforts in our 
study were limited by the lack of efficacy of the regimen and 
small number of samples.
Mutations in PIK3CA have been noted in a small pro-
portion of patients with NSCLC and small-cell lung cancer. 
Evaluation of inhibitors of the PI3K–Akt–mTOR axis in these 
patients is currently under investigation. If these studies show 
promising results, then further development of this class of 
compounds on the basis of pathway activation status in tumor 
tissues could result in an individualized therapeutic approach 
for lung cancer.
REFERENCES
 1. Sun SY, Fu H, Khuri FR. Targeting mTOR signaling for lung cancer ther-
apy. J Thorac Oncol 2006;1:109–111.
 2. VanderWeele DJ, Zhou R, Rudin CM. Akt up-regulation increases resis-
tance to microtubule-directed chemotherapeutic agents through mamma-
lian target of rapamycin. Mol Cancer Ther 2004;3:1605–1613.
 3. Soria JC, Shepherd FA, Douillard JY, et al. Efficacy of everolimus 
(RAD001) in patients with advanced NSCLC previously treated with che-
motherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 
2009;20:1674–1681.
 4. Zhang X, Zhang S, Liu Y, et al. Effects of the combination of RAD001 and 
docetaxel on breast cancer stem cells. Eur J Cancer 2012;48:1581–1592.
 5. Morgan TM, Pitts TE, Gross TS, Poliachik SL, Vessella RL, Corey E. 
RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and 
the inhibitory effects are increased by combination with docetaxel and 
zoledronic acid. Prostate 2008;68:861–871.
 6. Ramalingam SS, Harvey RD, Saba N, et al. Phase 1 and pharmacoki-
netic study of everolimus, a mammalian target of rapamycin inhibitor, in 
combination with docetaxel for recurrent/refractory nonsmall cell lung 
cancer. Cancer 2010;116:3903–3909.
 7. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evalu-
ate the response to treatment in solid tumors. European Organization 
for Research and Treatment of Cancer, National Cancer Institute of the 
United States, National Cancer Institute of Canada. J Natl Cancer Inst 
2000;92:205–216.
 8. Baselga J, Campone M, Piccart M, et al.; Everolimus in postmeno-
pausal hormone-receptor-positive advanced breast cancer. N Engl J Med 
2012;366:520–529.
 9. Motzer RJ, Escudier B, Oudard S, et al.; RECORD-1 Study Group. 
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, 
randomised, placebo-controlled phase III trial. Lancet 2008;372:449–456.
